{"organizations": [], "uuid": "747f7ecd27b46e3671fbebc5c92330a4b667a9db", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180124.html", "section_title": "Archive News &amp; Video for Wednesday, 24 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-living-cell-technologies-to-sell-5/brief-living-cell-technologies-to-sell-50-pct-stake-in-jv-for-3-mln-idUSFWN1PJ1AQ", "country": "US", "domain_rank": 408, "title": "BRIEF-Living Cell Technologies To Sell 50 Pct Stake In JV For $3 Mln", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.995, "site_type": "news", "published": "2018-01-25T10:59:00.000+02:00", "replies_count": 0, "uuid": "747f7ecd27b46e3671fbebc5c92330a4b667a9db"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-living-cell-technologies-to-sell-5/brief-living-cell-technologies-to-sell-50-pct-stake-in-jv-for-3-mln-idUSFWN1PJ1AQ", "ord_in_thread": 0, "title": "BRIEF-Living Cell Technologies To Sell 50 Pct Stake In JV For $3 Mln", "locations": [], "entities": {"persons": [], "locations": [{"name": "australia", "sentiment": "none"}, {"name": "new zealand", "sentiment": "none"}, {"name": "argentina", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "living cell technologies ltd", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 25 (Reuters) - Living Cell Technologies Ltd:\n* AGREED TO SELL ITS 50% SHAREHOLDING IN DIATRANZ OTSUKA LIMITED TO OTSUKA PHARMACEUTICAL FACTORY FOR $3 MILLION​\n* CO AND DOL TO SIGN MOU TO EXCLUSIVELY LICENSE CO TO USE DIABECELL IN AUSTRALIA, ARGENTINA AND NEW ZEALAND ONCE FDA APPROVED​ Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-25T10:59:00.000+02:00", "crawled": "2018-01-25T13:12:49.000+02:00", "highlightTitle": ""}